Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04381936 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Randomised Evaluation of COVID-19 Therapy

Study acronym: RECOVERY
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 30, 2026 to Sep 30, 2028v18 Show 8 more changesShow less
    • Primary endpoints revised (3)
    • Study sites: 7 to 16
    • Study completion date: Jun 30, 2036 to Sep 30, 2038
    • Interventions: Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baloxavir Marboxil (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma… to Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baloxavir Marboxil (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma…
    • Eligibility criteria expanded, about 170 words
    • Secondary endpoints revised (3)
    • Study description expanded, about 18 words
    • Publications: 28 to 29
  2. Phase: Phase 2/3 to Phase 3v17 Show 12 more changesShow less
    • Primary completion date: Nov 2023 to Jun 30, 2026
    • Primary endpoints: 1 to 3
    • Enrollment target: 50000 to 70000
    • Study sites: 9 to 7
    • Study completion date: Nov 2032 to Jun 30, 2036
    • Interventions: Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)… to Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baloxavir Marboxil (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma…
    • Eligibility criteria expanded, about 84 words
    • Secondary endpoints: 2 to 3
    • Study description expanded, about 161 words
    • Collaborators: 8 to 9
    • Publications: 29 to 28
    • Study arms: 19 to 23
  3. Primary completion date: Nov 2022 to Nov 2023
    • Study sites: 8 to 9
    • Study description expanded, about 71 words
    • Publications: 28 to 29
    v16
  4. Interventions: Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)… to Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)…v15 Show 5 more changesShow less
    • Eligibility criteria expanded, about 73 words
    • Study description expanded, about 42 words
    • Site details revised at 1 of 8 sites
    • Publications: details revised at 1 of 28 entries
    • Study arms: 17 to 19
  5. Enrollment target: 45000 to 50000v14 Show 5 more changesShow less
    • Interventions: Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)… to Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)…
    • Study description shortened, about 85 words
    • Site details revised at 1 of 8 sites
    • Publications: 29 to 28
    • Study arms: 16 to 17
Show 12 earlier versionsHide 12 earlier versions
  1. Primary completion date: Dec 2021 to Nov 2022
    • Study completion date: Dec 2031 to Nov 2032
    v13
  2. Study sites: 3 to 8
    • Study description expanded, about 4 words
    v12
  3. Enrollment target: 40000 to 45000
    • Interventions: Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)… to Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)…
    • Study description expanded, about 67 words
    • Publications revised (29)
    v11
  4. Interventions: Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)… to Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)…
    • Study description expanded, about 26 words
    • Publications: 28 to 29
    • Study arms: 14 to 16
    v10
  5. Study sites: 1 to 3
    • Interventions: Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)… to Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)…
    • Study description expanded, about 66 words
    • Study arms: 13 to 14
    v9
  6. Enrollment target: 20000 to 40000v8 Show 4 more changesShow less
    • Interventions: Aspirin (Drug), Azithromycin (Drug), Colchicine (Drug), Convalescent plasma (Biological), Corticosteroid (Drug), Hydroxychloroquine (Drug)… to Anakinra (Drug), Aspirin (Drug), Azithromycin (Drug), Baricitinib (Drug), Colchicine (Drug), Convalescent plasma (Biological)…
    • Study description expanded, about 25 words
    • Publications: details revised at 1 of 28 entries
    • Study arms: 11 to 13
  7. Interventions: Aspirin (Drug), Azithromycin (Drug), Convalescent plasma (Biological), Corticosteroid (Drug), Hydroxychloroquine (Drug), Immunoglobulin… to Aspirin (Drug), Azithromycin (Drug), Colchicine (Drug), Convalescent plasma (Biological), Corticosteroid (Drug), Hydroxychloroquine (Drug)…
    • Study description revised
    • Study arms: 10 to 11
    v7
  8. Enrollment target: 15000 to 20000v6 Show 5 more changesShow less
    • Interventions: Azithromycin (Drug), Convalescent plasma (Biological), Corticosteroid (Drug), Hydroxychloroquine (Drug), Immunoglobulin (Biological)… to Aspirin (Drug), Azithromycin (Drug), Convalescent plasma (Biological), Corticosteroid (Drug), Hydroxychloroquine (Drug), Immunoglobulin…
    • Study description expanded, about 22 words
    • Site contact updated
    • Publications: details revised at 2 of 28 entries
    • Study arms: 9 to 10
  9. Interventions: Azithromycin (Drug), Convalescent plasma (Biological), Corticosteroid (Drug), Hydroxychloroquine (Drug), Immunoglobulin (Biological)… to Azithromycin (Drug), Convalescent plasma (Biological), Corticosteroid (Drug), Hydroxychloroquine (Drug), Immunoglobulin (Biological)…v5 Show 4 more changesShow less
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study description expanded, about 6 words
    • Collaborators: 7 to 8
    • Study arms: 8 to 9
  10. Interventions: Azithromycin (Drug), Convalescent plasma (Biological), Corticosteroid (Drug), Hydroxychloroquine (Drug), Lopinavir-Ritonavir (Drug)… to Azithromycin (Drug), Convalescent plasma (Biological), Corticosteroid (Drug), Hydroxychloroquine (Drug), Immunoglobulin (Biological)…
    • Publications: details revised at 1 of 28 entries
    • Study arms: 7 to 8
    • Study description expanded, about 5 words
    v4
  11. Primary completion date: Dec 2020 to Dec 2021v3 Show 4 more changesShow less
    • Enrollment target: 12000 to 15000
    • Study completion date: Jun 2021 to Dec 2031
    • Secondary endpoints: 3 to 2
    • Study description expanded, about 49 words
  12. Interventions: Azithromycin (Drug), Corticosteroid (Drug), Hydroxychloroquine (Drug), Lopinavir-Ritonavir (Drug), Tocilizumab (Drug) to Azithromycin (Drug), Convalescent plasma (Biological), Corticosteroid (Drug), Hydroxychloroquine (Drug), Lopinavir-Ritonavir (Drug)…v2 Show 5 more changesShow less
    • Eligibility criteria revised
    • Secondary endpoints revised (3)
    • Study description expanded, about 16 words
    • Study title revised
    • Study arms: 6 to 7
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only) Influenza: Baloxavir marboxil, Oseltamivir, Corticosteroids (dexamethasone) Community-acquired pneumonia: Corticosteroids (dexamethasone)
Trial Details
NCT Number NCT04381936
Lead Sponsor University of Oxford
Collaborators: UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome Trust, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab
Conditions
(from sponsor)		 Pneumonia
Related terms Community-Acquired Pneumonia, COVID-19, Pneumonia
Enrollment 70,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov